Astra’s Caspian study is the star of next week’s World Lung conference, which has also given targeted approaches important supporting roles.
cMet emerges as the latest genetic mutation that could soon see targeted treatments become available.
When the World Congress on Lung Cancer kicks off in Toronto later this month all eyes will be on Roche’s Impower-133 study.
Epigenetics has so far failed to live up to the hype. But one UK player, Storm Therapeutics, still hopes to make a mark in a new field, RNA therapeutics.
A cooling of the M&A climate allows Asia-based groups to come to the fore.